CD39, CD73, and CD38 track tumor burden and reveal immune remodeling during mogamulizumab therapy in Sézary syndrome
Journal for ImmunoTherapy of Cancer · 2026-11 · 14 (11) · e016705
DOI: 10.1136/jitc-2026-016705 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 02.11.2026. Verfasst von Sara Marchisio und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: IMMUNO-CANCER-PRIN-2021, KWF Dutch Cancer Society, Research Projects of National Relevant Interest.
Abstract (Originalsprache)
Background
Sézary syndrome (SS) is an aggressive leukemic cutaneous T-cell lymphoma characterized by circulating malignant CD4 + T cells. Although mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, improves progression-free survival in SS, reliable pharmacodynamic biomarkers for monitoring treatment response and relapse remain lacking. Recent evidence demonstrated that CD39, CD73, and CD38 ectonucleotidases represent tumor-intrinsic markers for SS cell identification; here, we investigated their utility for longitudinal disease monitoring during Moga therapy, while characterizing treatment-induced immune remodeling.
Methods
Peripheral blood immune cell subsets from 14 patients with SS receiving Moga were longitudinally profiled by conventional (6-color) and spectral (22-color) flow cytometry over a median follow-up of 26 months. Ectonucleotidase expression was assessed on malignant and non-malignant immune cell subsets throughout treatment, including response and relapse.
Results
In responders, residual tumor cells consistently retained their patient-specific CD39 + and/or CD73+ aberrant profiles with persistently low CD38 expression throughout treatment. Longitudinal assessment of these markers on total CD4+ T cells closely reflected hematologic disease activity, declining during response and returning to baseline levels at relapse, consistent with re-emergence of phenotypically stable malignant clones. Patients with cutaneous-only progression maintained stable circulating ectonucleotidase profiles, reflecting sustained hematologic disease control despite skin relapse. Beyond the malignant compartment, Moga induced profound immune remodeling across conventional and regulatory CD4+ T, CD8+ T, natural killer (NK), NK T cell, and B cells, with subset-specific ectonucleotidase modulation during response and relapse. Notably, re-expansion of CD39+ regulatory T cells accompanied disease progression in selected patients, contrasting with their sustained depletion in sustained responders. In contrast, in patients with primary resistance, ectonucleotidase profiles remained unchanged, while distinct resistance mechanisms were identified, including impaired Moga binding to CCR4 and reduced NK-cell CD16 expression.
Conclusions
Combined assessment of CD39, CD73, and CD38 defines a candidate pharmacodynamic biomarker signature for longitudinal monitoring of hematologic disease during Moga therapy in SS. Longitudinal profiling further reveals treatment-induced remodeling across non-malignant immune subsets associated with disease progression, supporting the integration of ectonucleotidase profiling into biomarker-driven monitoring strategies in SS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy.
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Turin, Turin, Italy yuliya.yakymiv@unito.it.
- Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
- Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
- Interdipartimental Center for Molecular Biotechnologies "Guido Tarone", University of Turin, Turin, Italy.
Förderung
- IMMUNO-CANCER-PRIN-2021
- KWF Dutch Cancer Society
- Research Projects of National Relevant Interest
Zitieren
APA
Marchisio, S., Yakymiv, Y., Lin, L., Ortolan, E., Ponti, R., De Bie, F. J., Van Der Sluijs-Gelling, A. J., Pala, V., Scheeren, F., Vermeer, M. H., Funaro, A., Quaglino, P., Ribero, S., & Roccuzzo, G. (2026). CD39, CD73, and CD38 track tumor burden and reveal immune remodeling during mogamulizumab therapy in Sézary syndrome. Journal for ImmunoTherapy of Cancer, 14(11), e016705. https://doi.org/10.1136/jitc-2026-016705
Vancouver
Marchisio S, Yakymiv Y, Lin L, Ortolan E, Ponti R, De Bie FJ, et al. CD39, CD73, and CD38 track tumor burden and reveal immune remodeling during mogamulizumab therapy in Sézary syndrome. Journal for ImmunoTherapy of Cancer. 2026;14(11):e016705. doi:10.1136/jitc-2026-016705
BibTeX
@article{Marchisio2026,
author = {Marchisio, Sara and Yakymiv, Yuliya and Lin, Liyun and Ortolan, Erika and Ponti, Renata and De Bie, Fenna J and Van Der Sluijs-Gelling, Alita J and Pala, Valentina and Scheeren, Ferenc and Vermeer, Maarten H and Funaro, Ada and Quaglino, Pietro and Ribero, Simone and Roccuzzo, Gabriele},
title = {CD39, CD73, and CD38 track tumor burden and reveal immune remodeling during mogamulizumab therapy in Sézary syndrome},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {11},
pages = {e016705},
doi = {10.1136/jitc-2026-016705}
}
EUVIMED